Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75208
UPID:
COQ9_HUMAN
Alternative names:
-
Alternative UPACC:
O75208; A8K3L2; Q7L5V7; Q7Z5T6; Q8NBL4; Q9NTJ2; Q9P056
Background:
Ubiquinone biosynthesis protein COQ9, mitochondrial, is a lipid-binding protein crucial for the production of coenzyme Q, also known as ubiquinone. This essential lipid-soluble electron transporter is vital for aerobic cellular respiration, binding phospholipids to facilitate coenzyme Q synthesis.
Therapeutic significance:
Linked to Coenzyme Q10 deficiency, primary, 5, a disorder with diverse manifestations, understanding the role of Ubiquinone biosynthesis protein COQ9 could open doors to potential therapeutic strategies. Targeting COQ9's function may offer new avenues for treating this complex condition.